NCE-1 Intelligence & Market Opportunity

Voquezna

Vonoprazan, Amoxicillin, And Clarithromycin

Antiulcer

Oral Capsule, Tablet, Tablet

Approval Date

03-May-22

NCE-1 Date

03-May-26

NCE Date

03-May-27

Commercial snapshot

Market performance & projections

Revenue ($M)

1098

CAGR (%)

0.1453

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1259

2027

1454

2028

1738

2029

1889

2030

2005

2031

2028

2032

2012

Molecule profile

Details & specifications

Molecule

Vonoprazan, Amoxicillin, And Clarithromycin

Innovator

PHATHOM PHARMACEUTICALS INC.

Dosage Form

Oral Capsule, Tablet, Tablet

Strength

Vonoprazan EQ 20 mg base, Amoxicillin 500 mg, Clarithromycin 500 mg

Therapeutic Category

Antiulcer

Usage

To treat Helicobacter pylori infection

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.